Edwards Lifesciences (NYSE:EW) CFO Scott Ullem Sells 13,000 Shares

Edwards Lifesciences Corporation (NYSE:EW) CFO Scott Ullem sold 13,000 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,314,725.84. This represents a 24.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Edwards Lifesciences Stock Up 0.9%

Shares of Edwards Lifesciences stock traded up $0.71 during trading on Monday, reaching $84.10. The company had a trading volume of 3,140,253 shares, compared to its average volume of 4,557,639. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $87.09. The firm’s fifty day moving average is $77.78 and its 200-day moving average is $77.41. The company has a market cap of $48.80 billion, a price-to-earnings ratio of 12.10, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

EW has been the topic of several analyst reports. Robert W. Baird set a $83.00 target price on Edwards Lifesciences in a research report on Friday, October 31st. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. The Goldman Sachs Group set a $104.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a report on Friday, October 31st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $91.39.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently bought and sold shares of EW. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences during the 1st quarter valued at $26,000. SouthState Corp bought a new stake in Edwards Lifesciences in the 1st quarter valued at about $27,000. Rosenberg Matthew Hamilton bought a new stake in Edwards Lifesciences in the 2nd quarter valued at about $28,000. True Wealth Design LLC lifted its holdings in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the last quarter. Finally, Costello Asset Management INC bought a new position in Edwards Lifesciences during the first quarter worth about $29,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.